Optimising Phenotypic Screening - Single-cell analysis versus 3D multicell analysis By Dr Richard M. Eglen In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the… Read More
Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this… Read More
2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to look ahead, to… Read More
Automating Automation - How close are we to Artificial Intelligence impact? By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that emerging from automated… Read More
Automated Cell-based Assays: Novel tools overcome the barriers to drug discovery success By Helen Stewart-Miller and Kate Tointon In this article, we look at how commercial products and services are facilitating the automation of cell-based assays to advance drug discovery and accelerate the delivery of new medicines to patients. Cell-based… Read More
3D Organoid Cell Culture - Optimising disease models for research and drug discovery By Dr Amanda Linkous, Hilary Sherman, Iris Li and Dr Richard M. Eglen The use of human-induced pluripotent stem cells (HiPSCs) continues to grow in three-dimensional (3D) spheroid and organoid culture. Although advances in 3D cell culture… Read More
Increasing Drug Discovery Success With 3D Cell Culture Systems By Dr Richard M. Eglen, Dr Feng Li and Dr Tony Frutos Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when… Read More
3D Cell Culture - Engineering Composable, Disease-Tunable 3D Human Microtissues for Drug Discovery By Dr Patrick Guye, Dr Eva Thoma and Dr Olivier Frey In this article, we will share some of what we have learned over the past 10 years as pioneers in the 3D cell culture space and… Read More
The Future Of Drug Discovery - Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds,… Read More
How Phenotypic CRISPR Screening is Revolutionising Drug Discovery By Dr Steffen Lawo and Dr Carlos le Sage Research in drug discovery and biotechnology increasingly exploits gene editing at industrial scale in order to identify and validate new biological targets for precision medicines. The discovery of CRISPR-Cas9 systems has fuelled a… Read More
The Data Driven Transformation In Drug Discovery Dr Satnam Surae This article, presents a review of the current approaches to data management and application within the drug development and research setting, highlighting major critical challenges and emerging solutions for organisations that are determined to harness big data and machine learning. Read More
The Mass Spectrometry Innovations Simplifying Drug Discovery Workflows Helen Stewart-Miller and Dr Richard Massey Mass spectrometry (MS) has long been a valuable tool for drug discovery, and steady advances in its capabilities and performance have generated powerful insights for the pharmaceutical industry. The latest mass spectrometry innovations are now helping… Read More
Astrazeneca R&D - Improving Drug Development Productivity With Better Predictivity By Dr Menelas Pangalos & Steve Rees et al. Changing demands in global healthcare over the past 15 years have led to greater complexity and spiralling costs in drug development. The average price tag of taking a new drug from… Read More
Artificial Intelligence & Biopharma R&D IT By The PRISME Forum This article discusses issues around artificial intelligence & Biopharma R&D IT, and outlines how AI can be a potentially transformative technology for the biopharmaceutical and healthcare industries. "...R&D productivity remains an ongoing concern. Artificial Intelligence and the accompanying analytics are… Read More
Practicalities of Conducting Replication Studies in Preclinical Cancer Biology By Dr Nicole Perfito, Dr Rachel Tsui & Dr Elizabeth Iorns The first results for the Reproducibility Project: Cancer Biology, offer insights into the time and cost of conducting replication studies in preclinical cancer biology. While many agree that developing a… Read More
High-Throughput Spheroid Culture - Applications of 3D Cell Culture By Hilary Sherman, Dr Richard M. Eglen & Audrey Bergeron In this article, we describe applications of high-throughput screening using 3D cell culture to assess cell viability. In addition, we highlight the importance of including multiple cell types in 3D assays… Read More